Topical tacrolimus for the treatment of secondary lymphedema

Secondary lymphedema is a debilitating disease with no cure. Here the authors show that topical application of an FDA-approved anti-T cell drug tacrolimus potently prevents development and alleviates pathologic changes of established lymphedema in mice, suggesting a new treatment for human patients.

Guardado en:
Detalles Bibliográficos
Autores principales: Jason C. Gardenier, Raghu P. Kataru, Geoffrey E. Hespe, Ira L. Savetsky, Jeremy S. Torrisi, Gabriela D. García Nores, Dawit K. Jowhar, Matthew D. Nitti, Ryan C. Schofield, Dean C. Carlow, Babak J. Mehrara
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Q
Acceso en línea:https://doaj.org/article/8ae0ff4c3d0e4e30a638ec12178b9f93
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares